# telehealth

Type: Technology

Source: Legal & RegTech Intelligence Brief — https://getlegalbrief.com/entity/telehealth
Canonical HTML page: https://getlegalbrief.com/entity/telehealth

## Timeline

- **2026-05-03**: Federal Appeals Court Bans Mailing Mifepristone — A federal appeals court made it illegal to mail mifepristone, a key medication abortion pill, threatening telehealth access.
- **2026-05**: Supreme Court Issues Stay on Mifepristone Ban — The Supreme Court stayed the appeals court ruling, allowing mailing to continue while the legal challenge proceeds.
- **2026-03-13**: Missouri Stay Request — DOJ files request in Missouri court to pause litigation pending FDA review.
- **2026-03-11**: Legislative Action — Senator Josh Hawley introduces a Senate bill to outright ban the abortion pill.
- **2026-01-20**: Louisiana Request — DOJ asks Louisiana court to pause a similar lawsuit; request is largely ignored by the state.
- **2025-11-15**: Amended Complaint — AG Catherine Hanaway files amended complaint targeting mail-order abortion drugs.
- **2025-10-01**: Lawsuit Filed — Missouri, Kansas, and Idaho file suit against the FDA over mifepristone approval.
- **2022-06-24**: Supreme Court Overturns Roe v. Wade in Dobbs Decision — The landmark ruling eliminated the constitutional right to abortion, allowing states to enact bans.

## Recent coverage (2 stories)

### Abortions Surge 100% Post-Roe: How Telehealth Pills Exploit Legal Gaps
2026-06-28 09:16:18 · Sentiment: Neutral · Impact: 7/10 · Sources: 23

Despite state bans, U.S. abortions nearly doubled, fueled by telehealth pill delivery across state lines. This exposes legal tensions between state authority, FDA preemption, and 19th-century obscenity statutes.
Full story: https://getlegalbrief.com/story/abortions-surge-telehealth-legal

### DOJ Seeks Strategic Pause in State-Led Mifepristone Litigation Amid FDA Review
2026-03-13 00:34:01 · Sentiment: Negative · Impact: 8/10 · Sources: 2

The U.S. Department of Justice has requested federal courts in Missouri to pause litigation challenging the FDA's approval of mifepristone, citing an ongoing internal agency review. This tactical shift suggests a preference for administrative rulemaking over high-profile court battles as the administration navigates the legal complexities of reproductive health regulation.
Full story: https://getlegalbrief.com/story/doj-mifepristone-litigation-stay-missouri

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getlegalbrief.com/guides/methodology for the full editorial methodology.